Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shenzhen Beimei Pharmaceutical

Request full access

Specialized pharmaceutical developer of pediatric prescription medicines

Shenzhen, ChinaFounded 2010Health

About Shenzhen Beimei Pharmaceutical

Shenzhen Beimei Pharmaceutical Co., Ltd. is a pharmaceutical company founded in 2010 by Claire Wu that specializes in pediatric prescription medicines. Wu, who serves as CEO and General Manager, has over 20 years of experience in pharmaceutical marketing, sales, and R&D. The company aims to address the challenges of pediatric medication by developing high-quality, accurately-dosed, and palatable products for children.

Beimei Pharmaceutical operates with a dual strategy of in-house research and development combined with global collaboration through in-licensing and asset acquisitions. This approach allows the company to integrate R&D, manufacturing, and commercialization. The company's product pipeline includes over 40 pediatric drugs, with 7 already on the market, covering therapeutic areas such as dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, and endocrinology. A key product is TWYNEO®, an FDA-approved cream for acne vulgaris, for which Beimei acquired the commercial rights in China and Israel in May 2024. Beimei has established a nearly 3,000-square-meter R&D center and has built proprietary technology platforms for pediatric sustained-release formulations, oral thin films, and topical transdermal gels.

The company's business model is centered on the development and commercialization of these specialized pediatric drugs. Revenue is generated through the sale of its approved products. Beimei Pharmaceutical has formed strategic long-term partnerships with major international pharmaceutical firms, including Hetero, Cipla, Dr. Reddy's, and Sol-Gel. The company is venture capital-backed, having completed multiple funding rounds, including Angel, Series A, B/B+, and C, with backing from institutions like Efung Capital and Nanshan Zhanxin Investment.

Source: Dealroom company data

Shenzhen Beimei Pharmaceutical in the Shenzhen ecosystem

Live from Dealroom

The Shenzhen Beimei Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Efung Capital

Series B and later3 investors entered at this stage

  • Nanshan Strategic Emerging
  • Jiangsu Aosaikang Pharmaceutical
  • Jiangsu Golden Bridge Private Equity Fund
Employees 19 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shenzhen Beimei Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shenzhen Beimei Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.